REGISTER
MedJ at ESMO 2025 with Dr. Tony Mok
Recent data bring fresh attention to MedJ at ESMO 2025 with Dr. Tony Mok. It pulls together the main findings on ESMO, CUHK, OS and shows what they may mean for diagnosis, monitoring, prevention, or treatment.

Tony Mok, Md, The Chinese University of Hong Kong (CUHK), China

Final OS Data from the ALEX Study Revealed - Alectinib Brings New Hope for Long-Term Survival and Potential Clinical Cure in Advanced ALK-Positive NSCLC Patients! Unraveling the Evolution of First-Line Treatment Paradigms and Future Breakthrough Directions.

0
0
Loading